AI-generated summary
The authors analyzed side effects, weight and blood pressure in a small double-blind trial of near-infrared transcranial photobiomodulation or sham for depression, given twice weekly for 8 weeks. More participants in the treatment group reported side effects than sham, though this was only a trend, and no serious adverse events occurred. Diastolic blood pressure rose in the treatment group, which the authors describe as statistically but not clinically significant.
- Participants
- 18
- Who or what was studied
- Individuals with major depressive disorder enrolled in a double-blind clinical trial; 18 received near-infrared transcranial photobiomodulation (n = 9) or sham (n = 9), with weight and blood pressure recorded in 14.
- Limits stated in the abstract
- The authors describe this as a small-sample, exploratory secondary analysis, and the side-effect comparison reached only a trend for statistical significance.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Transcranial photobiomodulation, Sham, Statistical significance, Light-emitting diode, Depression. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.